← All Optinose, INC filings

Optinose, INC S-1 registration statements

Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.

OPTN
Optinose, INC
S-1/A: Option Therapeutics Launches IPO for Liver Disease Drug BIV201
Option Therapeutics Inc., a BioVie subsidiary, is launching its initial public offering to fund the Phase 3 clinical trial of BIV201, an investigational drug for advanced liver cirrhosis complications, aiming to raise $17.0 million.